Thu 22'nd Mar 2018
Juniper Pharmaceuticals Stock Analysis
Technical stock analysis for Thu 22'nd Mar 2018
Juniper Pharmaceuticals fell by -1.18% in the last day from $12.70 to $12.55 The price has risen in 6 of the last 10 days and is up by 25.5% over the past 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -54 877 shares and in total 93 368 shares bought and sold for approximately $1.17 million.
|Shorts||1.45% ( 2018-02-28 )|
Juniper Pharmaceuticals lies in the upper part of a wide and strong rising trend in the short term, and this will normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $12.82 will firstly indicate a stronger raising rate. Given the current short-term trend, the stock is expected to rise 122.06% during the next 3 months and, with 90% probability hold a price between $23.04 and $28.47 at the end of this period.
Juniper Pharmaceuticals holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $12.25 and $9.43. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Wednesday March 21, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
The stock holds a RSI14 at 77 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
Support & Resistance
Juniper Pharmaceuticals finds support from accumulated volume at $12.50. On the upside the stock meets some resistance just above today's level from accumulated volume at $12.70.
The stock is about to test the resistance from accumulated volume at $12.70 and this may cause the stock to take a minor break or get into a more sideways move for a few days.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.39 between high and low, or 3.13%. For the last week the stock has had a daily average volatility of 6.71%.
The stock is overbought on RSI14 and lies in the upper part of the trend. Normally this will pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.
Our recommended stoploss: $11.82 (-5.80%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 77 and this increases the risk substantially. There is a sell signal from pivot top found 1 days ago.)
Very Low Low Medium High Very High
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Strong Buy Candidate to a Buy Candidate.
Trade JNP CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder